RET and non-small cell lung carcinoma: Results from the IMMUNOTARGET registry, which included 43 NSCLC patients with BRAF alterations, showed higher activity of immunotherapy (ORR: 24.3%) compared to NSCLC patients carrying different oncogene alterations, such as EGFR, MET, RET, ROS1, ALK and HER2 ones [56].